874 related articles for article (PubMed ID: 20925543)
1. Severe hypoglycemia and risks of vascular events and death.
Zoungas S; Patel A; Chalmers J; de Galan BE; Li Q; Billot L; Woodward M; Ninomiya T; Neal B; MacMahon S; Grobbee DE; Kengne AP; Marre M; Heller S;
N Engl J Med; 2010 Oct; 363(15):1410-8. PubMed ID: 20925543
[TBL] [Abstract][Full Text] [Related]
2. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
; Patel A; MacMahon S; Chalmers J; Neal B; Billot L; Woodward M; Marre M; Cooper M; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Liu L; Mancia G; Mogensen CE; Pan C; Poulter N; Rodgers A; Williams B; Bompoint S; de Galan BE; Joshi R; Travert F
N Engl J Med; 2008 Jun; 358(24):2560-72. PubMed ID: 18539916
[TBL] [Abstract][Full Text] [Related]
3. Impact of visit-to-visit glycemic variability on the risks of macrovascular and microvascular events and all-cause mortality in type 2 diabetes: the ADVANCE trial.
Hirakawa Y; Arima H; Zoungas S; Ninomiya T; Cooper M; Hamet P; Mancia G; Poulter N; Harrap S; Woodward M; Chalmers J
Diabetes Care; 2014 Aug; 37(8):2359-65. PubMed ID: 24812434
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.
Mohammedi K; Woodward M; Marre M; Colagiuri S; Cooper M; Harrap S; Mancia G; Poulter N; Williams B; Zoungas S; Chalmers J
Cardiovasc Diabetol; 2017 Jul; 16(1):95. PubMed ID: 28750645
[TBL] [Abstract][Full Text] [Related]
5. Severe hypoglycemia and the risk of cardiovascular disease and mortality in type 2 diabetes: a nationwide population-based cohort study.
Yun JS; Park YM; Han K; Cha SA; Ahn YB; Ko SH
Cardiovasc Diabetol; 2019 Aug; 18(1):103. PubMed ID: 31412855
[TBL] [Abstract][Full Text] [Related]
6. Impact of hypoglycemia associated with antihyperglycemic medications on vascular risks in veterans with type 2 diabetes.
Zhao Y; Campbell CR; Fonseca V; Shi L
Diabetes Care; 2012 May; 35(5):1126-32. PubMed ID: 22432106
[TBL] [Abstract][Full Text] [Related]
7. Hypoglycemia: Adverse Cardiovascular Outcomes in Non-Critically Ill People with Type 2 Diabetes.
Akhavan P; Aghili R; Malek M; Ebrahim Valojerdi A; Khamseh ME
Arch Iran Med; 2016 Feb; 19(2):82-6. PubMed ID: 26838076
[TBL] [Abstract][Full Text] [Related]
8. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes.
Zoungas S; Chalmers J; Neal B; Billot L; Li Q; Hirakawa Y; Arima H; Monaghan H; Joshi R; Colagiuri S; Cooper ME; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Lisheng L; Mancia G; Marre M; Matthews DR; Mogensen CE; Perkovic V; Poulter N; Rodgers A; Williams B; MacMahon S; Patel A; Woodward M;
N Engl J Med; 2014 Oct; 371(15):1392-406. PubMed ID: 25234206
[TBL] [Abstract][Full Text] [Related]
9. Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
van der Leeuw J; Visseren FL; Woodward M; van der Graaf Y; Grobbee DE; Harrap S; Heller S; Mancia G; Marre M; Poulter N; Zoungas S; Chalmers J
Diabetologia; 2016 Dec; 59(12):2603-2612. PubMed ID: 27586250
[TBL] [Abstract][Full Text] [Related]
10. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
de Galan BE; Zoungas S; Chalmers J; Anderson C; Dufouil C; Pillai A; Cooper M; Grobbee DE; Hackett M; Hamet P; Heller SR; Lisheng L; MacMahon S; Mancia G; Neal B; Pan CY; Patel A; Poulter N; Travert F; Woodward M;
Diabetologia; 2009 Nov; 52(11):2328-2336. PubMed ID: 19688336
[TBL] [Abstract][Full Text] [Related]
11. Hypoglycemia and risk of death in critically ill patients.
; Finfer S; Liu B; Chittock DR; Norton R; Myburgh JA; McArthur C; Mitchell I; Foster D; Dhingra V; Henderson WR; Ronco JJ; Bellomo R; Cook D; McDonald E; Dodek P; Hébert PC; Heyland DK; Robinson BG
N Engl J Med; 2012 Sep; 367(12):1108-18. PubMed ID: 22992074
[TBL] [Abstract][Full Text] [Related]
12. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
[TBL] [Abstract][Full Text] [Related]
13. Risks of cardiovascular diseases associated with dipeptidyl peptidase-4 inhibitors and other antidiabetic drugs in patients with type 2 diabetes: a nation-wide longitudinal study.
Ou HT; Chang KC; Li CY; Wu JS
Cardiovasc Diabetol; 2016 Mar; 15():41. PubMed ID: 26932742
[TBL] [Abstract][Full Text] [Related]
14. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
Tandon N; Ali MK; Narayan KM
Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
[TBL] [Abstract][Full Text] [Related]
15. Effects of Intensive Glycemic Control on Clinical Outcomes Among Patients With Type 2 Diabetes With Different Levels of Cardiovascular Risk and Hemoglobin A
Tian J; Ohkuma T; Cooper M; Harrap S; Mancia G; Poulter N; Wang JG; Zoungas S; Woodward M; Chalmers J
Diabetes Care; 2020 Jun; 43(6):1293-1299. PubMed ID: 32193249
[TBL] [Abstract][Full Text] [Related]
16. Effects of intensive glucose lowering in type 2 diabetes.
; Gerstein HC; Miller ME; Byington RP; Goff DC; Bigger JT; Buse JB; Cushman WC; Genuth S; Ismail-Beigi F; Grimm RH; Probstfield JL; Simons-Morton DG; Friedewald WT
N Engl J Med; 2008 Jun; 358(24):2545-59. PubMed ID: 18539917
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial.
Zoungas S; de Galan BE; Ninomiya T; Grobbee D; Hamet P; Heller S; MacMahon S; Marre M; Neal B; Patel A; Woodward M; Chalmers J; ; Cass A; Glasziou P; Harrap S; Lisheng L; Mancia G; Pillai A; Poulter N; Perkovic V; Travert F
Diabetes Care; 2009 Nov; 32(11):2068-74. PubMed ID: 19651921
[TBL] [Abstract][Full Text] [Related]
18. Hypoglycemia as a driver of cardiovascular risk in diabetes.
Moheet A; Seaquist ER
Curr Atheroscler Rep; 2013 Sep; 15(9):351. PubMed ID: 23881546
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
Landman GW; de Bock GH; van Hateren KJ; van Dijk PR; Groenier KH; Gans RO; Houweling ST; Bilo HJ; Kleefstra N
PLoS One; 2014; 9(2):e82880. PubMed ID: 24533045
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of intensive glucose lowering on cardiovascular outcomes.
; Gerstein HC; Miller ME; Genuth S; Ismail-Beigi F; Buse JB; Goff DC; Probstfield JL; Cushman WC; Ginsberg HN; Bigger JT; Grimm RH; Byington RP; Rosenberg YD; Friedewald WT
N Engl J Med; 2011 Mar; 364(9):818-28. PubMed ID: 21366473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
